Skip to content

Study · Randomized controlled trial · n = 199 · 1986

11 results

Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.

Garnick MB

Urology1 Jan 1986Cited by 26 (Europe PMC)

PMID3079935 (opens in a new tab)DOI10.1016/s0090-4295(86)80006-1 (opens in a new tab)PepBankPUB-03079935
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with Stage D2 prostate cancer, objective and subjective disease measures decreased similarly with leuprolide and diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, disease measures decreased similarly with leuprolide and diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedDisease measures
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Objective measures of disease, such as acid phosphatase levels, and subjective measures, such as bone pain, performance status, and mobility, showed similar decreases in both groups.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with Stage D2 prostate cancer, no progression occurred in 86% with leuprolide versus 85% with diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, no progression occurred in 86% with leuprolide versus 85% with diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    IncreaseAbsence of progression
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg/dayAs given in this study (human).

    Measurements

    No progression
    86%
    leuprolide
    No progression
    85%
    DES

    Source sentences

    Summary
    No progression of disease was seen in 86 per cent of the leuprolide-treated group, compared with 85 per cent of the DES-treated group.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with Stage D2 prostate cancer, time to progression, treatment-limiting adverse reaction, or death was identical with leuprolide and diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, time to progression, treatment-limiting adverse reaction, or death was identical with leuprolide and diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    No significant changeTime to progression, treatment-limiting adverse reaction, or death
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    The time to disease progression, development of adverse reaction requiring discontinuation of treatment, or death was identical for the two groups.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, hot flashes occurred more often with leuprolide than diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, hot flashes were more common with leuprolide than with diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    IncreaseHot flashes
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Adverse events · Whole body
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Hot flashes were more common with leuprolide than with DES.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, gynecomastia occurred less often with leuprolide than diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, breast enlargement occurred less often with leuprolide than diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    DecreaseGynecomastia
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Gynecomastia and breast tenderness, nausea and vomiting, and peripheral edema occurred more often in the DES group.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, breast tenderness occurred less often with leuprolide than diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, breast tenderness occurred less often with leuprolide than diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    DecreaseBreast tenderness
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Gynecomastia and breast tenderness, nausea and vomiting, and peripheral edema occurred more often in the DES group.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, nausea occurred less often with leuprolide than diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, nausea occurred less often with leuprolide than diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    DecreaseNausea
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Gynecomastia and breast tenderness, nausea and vomiting, and peripheral edema occurred more often in the DES group.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  8. 08HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, vomiting occurred less often with leuprolide than diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, vomiting occurred less often with leuprolide than diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    DecreaseVomiting
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Gynecomastia and breast tenderness, nausea and vomiting, and peripheral edema occurred more often in the DES group.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  9. 09HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, peripheral edema occurred less often with leuprolide than diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, peripheral swelling occurred less often with leuprolide than diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    DecreasePeripheral edema
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Adverse events · Whole body
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Gynecomastia and breast tenderness, nausea and vomiting, and peripheral edema occurred more often in the DES group.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  10. 10HumanRandomized controlled trialSafety outcome

    In patients with Stage D2 prostate cancer, side effects caused discontinuation in 3% with leuprolide versus 13% with diethylstilbestrol.

    In plain wordsIn patients with advanced prostate cancer, side effects caused discontinuation in 3% with leuprolide versus 13% with diethylstilbestrol.

    Peptide
    Leuprolide
    Outcome
    DecreaseDiscontinuation because of side effects
    Study

    n = 199

    Comparator
    Diethylstilbestrol 3 mg/day
    Outcome group
    Adverse events · Whole body
    Studied dose
    1 mg/dayAs given in this study (human).

    Measurements

    Discontinuation
    3%
    leuprolide
    Discontinuation
    13%
    DES

    Source sentences

    Summary
    Of those taking DES, 13 per cent discontinued treatment because of side effects, compared with 3 per cent of those taking leuprolide.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with Stage D2 prostate cancer, leuprolide suppressed testosterone to castrate levels.

    In plain wordsIn patients with advanced prostate cancer, leuprolide suppressed testosterone to castrate levels.

    Peptide
    Leuprolide
    Outcome
    DecreaseTestosterone suppression
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Both DES and leuprolide suppressed testosterone to the desired castrate levels.
    1 context sentence
    Summary · context
    In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.